Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen: Results of the Phase 1 ReCLAIM Study
Publication
, Conference
Allingham, MJ; Mettu, PS; Cousins, SW
Published in: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
July 1, 2019
Duke Scholars
Published In
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
EISSN
1552-5783
ISSN
0146-0404
Publication Date
July 1, 2019
Volume
60
Issue
9
Location
Vancouver, CANADA
Publisher
ASSOC RESEARCH VISION OPHTHALMOLOGY INC
Conference Name
Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
Related Subject Headings
- Ophthalmology & Optometry
- 3212 Ophthalmology and optometry
- 11 Medical and Health Sciences
- 06 Biological Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Allingham, M. J., Mettu, P. S., & Cousins, S. W. (2019). Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen: Results of the Phase 1 ReCLAIM Study. In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE (Vol. 60). Vancouver, CANADA: ASSOC RESEARCH VISION OPHTHALMOLOGY INC.
Allingham, Michael John, Priyatham S. Mettu, and Scott W. Cousins. “Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen: Results of the Phase 1 ReCLAIM Study.” In INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, Vol. 60. ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 2019.
Allingham MJ, Mettu PS, Cousins SW. Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen: Results of the Phase 1 ReCLAIM Study. In: INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. ASSOC RESEARCH VISION OPHTHALMOLOGY INC; 2019.
Allingham, Michael John, et al. “Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen: Results of the Phase 1 ReCLAIM Study.” INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, vol. 60, no. 9, ASSOC RESEARCH VISION OPHTHALMOLOGY INC, 2019.
Allingham MJ, Mettu PS, Cousins SW. Elamipretide, a Mitochondrial-Targeted Drug, for the Treatment of Vision Loss in Dry AMD with High Risk Drusen: Results of the Phase 1 ReCLAIM Study. INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE. ASSOC RESEARCH VISION OPHTHALMOLOGY INC; 2019.
Published In
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
EISSN
1552-5783
ISSN
0146-0404
Publication Date
July 1, 2019
Volume
60
Issue
9
Location
Vancouver, CANADA
Publisher
ASSOC RESEARCH VISION OPHTHALMOLOGY INC
Conference Name
Annual Meeting of the Association-for-Research-in-Vision-and-Ophthalmology (ARVO)
Related Subject Headings
- Ophthalmology & Optometry
- 3212 Ophthalmology and optometry
- 11 Medical and Health Sciences
- 06 Biological Sciences